Clinical Trial: A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis

U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07315061) titled 'A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis' on Dec. 18, 2025.

Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.

Study Start Date: Dec. 22, 2025

Study Type: INTERVENTIONAL

Condition: PsA (Psoriatic Arthritis)

Intervention: DRUG: D-2570

Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product...